Comprehensive splicing analysis of the alternatively spliced CHEK2 exons 8 and 10 reveals three enhancer/silencer‐rich regions and 38 spliceogenic variants

Author:

Sanoguera‐Miralles Lara1ORCID,Llinares‐Burguet Inés1ORCID,Bueno‐Martínez Elena1,Ramadane‐Morchadi Lobna2,Stuani Cristiana3,Valenzuela‐Palomo Alberto1,García‐Álvarez Alicia1,Pérez‐Segura Pedro2,Buratti Emanuele3,de la Hoya Miguel2ORCID,Velasco‐Sampedro Eladio A1ORCID

Affiliation:

1. Splicing and Genetic Susceptibility to Cancer, Unidad de Excelencia Instituto de Biomedicina y Genética Molecular de Valladolid (IBGM) Consejo Superior de Investigaciones Científicas – Universidad de Valladolid (CSIC‐UVa) Valladolid Spain

2. Molecular Oncology Laboratory CIBERONC, Hospital Clínico San Carlos IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) Madrid Spain

3. Molecular Pathology Lab. International Centre of Genetic Engineering and Biotechnology Trieste Italy

Abstract

AbstractSplicing is controlled by a large set of regulatory elements (SREs) including splicing enhancers and silencers, which are involved in exon recognition. Variants at these motifs may dysregulate splicing and trigger loss‐of‐function transcripts associated with disease. Our goal here was to study the alternatively spliced exons 8 and 10 of the breast cancer susceptibility gene CHEK2. For this purpose, we used a previously published minigene with exons 6–10 that produced the expected minigene full‐length transcript and replicated the naturally occurring events of exon 8 [Δ(E8)] and exon 10 [Δ(E10)] skipping. We then introduced 12 internal microdeletions of exons 8 and 10 by mutagenesis in order to map SRE‐rich intervals by splicing assays in MCF‐7 cells. We identified three minimal (10‐, 11‐, 15‐nt) regions essential for exon recognition: c.863_877del [ex8, Δ(E8): 75%] and c.1073_1083del and c.1083_1092del [ex10, Δ(E10): 97% and 62%, respectively]. Then 87 variants found within these intervals were introduced into the wild‐type minigene and tested functionally. Thirty‐eight of them (44%) impaired splicing, four of which (c.883G>A, c.883G>T, c.884A>T, and c.1080G>T) induced negligible amounts (<5%) of the minigene full‐length transcript. Another six variants (c.886G>A, c.886G>T, c.1075G>A, c.1075G>T, c.1076A>T, and c.1078G>T) showed significantly strong impacts (20–50% of the minigene full‐length transcript). Thirty‐three of the 38 spliceogenic variants were annotated as missense, three as nonsense, and two as synonymous, underlying the fact that any exonic change is capable of disrupting splicing. Moreover, c.883G>A, c.883G>T, and c.884A>T were classified as pathogenic/likely pathogenic variants according to ACMG/AMP (American College of Medical Genetics and Genomics/Association for Molecular Pathology)‐based criteria. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Funder

Ministerio de Ciencia e Innovación

Fundación Científica Asociación Española Contra el Cáncer

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3